Solarvest Receives Cannabis Research License

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

(TheNewswire)




Vancouver, BC – TheNewswire - November 18th, 2019 – SOLARVEST BIOENERGY INC. (TSXV:SVS) (the “Company”), is pleased to announce that Health Canada has issued the Company a research license under the cannabis act and cannabis regulations for its Microalgae Cannabinoid Expression Program.  This license will allow Solarvest to transfer its computer modeling work into the laboratory and use its algal expression system to express pharmaceutical-grade cannabinoids.  FSD Pharma Inc. and Solarvest have allocated an initial budget of $1,000,000 for the CBD proof of concept research project.  

 

“Solarvest has developed a suite of international patents based on using algae as a production platform,” said Gerri Greenham, CEO Solarvest.  “If successful, the algae can be grown in sterile pharmaceutically approved cGMP facilities facilitating an FDA licensing program”. A full growth cycle of algae is around a hundred hours whereas the growth of cannabis plants is measured in months. This short time period condenses research and production times.   The Company’s commercial plan would be to supply approved pharmaceutical ingredients to FSD Pharma Inc. and other companies interested in developing cannabinoid based products.  

 

About Solarvest:

Solarvest BioEnergy Inc. is an algae biotechnology company whose algal-based production platform provides it with an extremely flexible system capable of being adapted to produce numerous products - from Omega 3 fatty acids to human therapeutic proteins.  The company has successfully demonstrated (news release dated March 16th. 2015) the expression of BMP, a high value therapeutic protein. In addition the company’s platform has successfully produced recombinant viral antigens (immune stimulating proteins,) Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC.as a way to produce CBD and THC in sterile bioreactors.

For further information contact:  

Garth Greenham, COO, Solarvest Bioenergy Inc.

Tel: 647 204 4095 Email: [email protected]

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company’s expectations and projections.

.

Copyright (c) 2019 TheNewswire - All rights reserved.